| [1] |
Brewster AM,Hortobagyi GN,Broglio KR,et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy [J].J Natl Cancer Inst,2008,100(16):1179-1183.
|
| [2] |
Mayer EL, Burstein HJ. Chemotherapy for metastatic breast cancer [J]. Hematol Oncol Clin North Am, 2007, 21(2):257-272.
|
| [3] |
Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours [J]. Nature,2000,406(6797):747-752.
|
| [4] |
Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [J]. Proc Natl Acad Sci USA, 2001,98(19): 10 869-10 874.
|
| [5] |
Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets [J]. Proc Natl Acad Sci USA,2003,100(14):8418-8423.
|
| [6] |
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2011 版) [J]. 中国癌症杂志,2011,21(5):367-416.
|
| [7] |
胡夕春, 王碧芸, 邵志敏. 2011 年《St. Gallen 共识》与中国抗癌协会乳腺癌专业委员会指南之比较[J/CD]. 中华乳腺病杂志:电子版,2011,5(4):404-407.
|
| [8] |
Cancer genome atlas network. Comprehensive molecular portraits of human breast tumours [J]. Nature, 2012, 490(7418):61-70.
|
| [9] |
Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J]. Ann Oncol, 2011,22(8):1736-1747.
|
| [10] |
Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27[J]. J Clin Oncol,2008,26(5):778-785.
|
| [11] |
Gralow JR, Zujewski JA, Winer E. Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions[J]. J Clin Oncol,2008,26(5):696-697.
|
| [12] |
Kong X, Moran MS, Zhang N, et al. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer,2011,47(14):2084-2090.
|
| [13] |
Mathew J, Asgeirsson KS, Jackson LR, et al. Neoadjuvant endocrine treatment in primary breast cancer - review of literature. Breast,2009,18(6):339-344.
|
| [14] |
Chen XS, Wu JY, Huang O, et al. Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy[J].Oncol Rep,2010,23(5):1213-1220.
|
| [15] |
Chen XS, Nie XQ, Chen CM, et al. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer [J]. Ann Oncol,2010,21(5):961-967.
|
| [16] |
Mazouni C, Kau SW, Frye D, et al. Inclusion of taxanes,particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptorpositive breast cancers [J]. Ann Oncol,2007,18(5):874-880.
|
| [17] |
Mauriac L, Debled M, Durand M, et al. Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women [J]. Ann Oncol,2002,13(2):293-298.
|
| [18] |
Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study [J].Ann Oncol,2001,12(11):1527-1532.
|
| [19] |
Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole,Tamoxifen, or Combined with Tamoxifen ( IMPACT )multicenter double-blind randomized trial[J]. J Clin Oncol,2005,23(22):5108-5116.
|
| [20] |
Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative ＂Arimidex＂ Compared to Tamoxifen(PROACT) trial [J]. Cancer,2006,106(10):2095-2103.
|
| [21] |
Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptorrich stage 2 to 3 breast cancer:clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031[J]. J Clin Oncol, 2011, 29(17):2342-2349.
|
| [22] |
Buzdar AU,Ibrahim NK,Francis D,et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy:results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J]. J Clin Oncol,2005,23(16):3676-3685.
|
| [23] |
Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone,in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort[J]. Lancet,2010,375(9712):377-384.
|
| [24] |
Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvantanthracyclinetaxane-based chemotherapy ( GeparQuinto, GBG 44): a randomised phase 3 trial[J]. Lancet Oncol, 2012, 13(2):135-144.
|
| [25] |
Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J]. Lancet,2012,379(9816):633-640.
|
| [26] |
Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvantpertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer(NeoSphere): a randomizedmulticentre, open-label, phase 2 trial [J]. Lancet Oncol,2012,13(1):25-32.
|
| [27] |
Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol,2008,26(8):1275-1281.
|
| [28] |
Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvantcisplatin in triple-negative breast cancer [J]. J Clin Oncol,2010,28(7):1145-1153.
|
| [29] |
沈镇宙, 宋三泰, 江泽飞,等. 乳腺癌临床实践指南(中国版) [S]. 北京:中国抗癌协会,2008.
|
| [30] |
Poole C, Hiller L, Howard H, et al. tAnGo trial collaborators.tAnGo: a randomized phase III trial of gemcitabine (gem) in paclitaxel-containing,epirubicin/cyclophosphamide-based,adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC)[J]. J Clin Oncol,2008,26(suppl):506.
|
| [31] |
Swain SM, Tang G, Geyer CE,et al. NSABP B-38:Definitive analysis of a randomized adjuvant trial comparing dose-dense(DD) AC→paclitaxel (P) plus gemcitabine (G) with DD AC→P and with docetaxel, doxorubicin, and cyclophosphamide(TAC) in women with operable, node-positive breast cancer[EB/OL]. [2012-11-20]. http:/ /meetinglibrary. asco. org/content/98794-114.
|
| [32] |
Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al.Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial[J]. J Clin Oncol,2012,30(1):11-18.
|
| [33] |
Liedtke C, Broglio K, Moulder S, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer[J]. Ann Oncol, 2009, 20(12):1953-1958.
|
| [34] |
Amir E, Miller N, Geddie W, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer[J]. J Clin Oncol,2012,30(6):587-592.
|
| [35] |
Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer [J]. N Engl J Med,2012,367(5):435-444.
|
| [36] |
Bergh J, Jonsson PE, Lidbrink EK, et al. FACT: an openlabel randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer [J]. J Clin Oncol,2012,30(16):1919-1925.
|
| [37] |
Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study[J]. J Clin Oncol,2012,30(22):2718-2724.
|
| [38] |
Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer [J]. N Engl J Med,2012,366(6):520-529.
|
| [39] |
Johnston S, Pippen JJ, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer[J]. J Clin Oncol,2009,27(33):5538-5546.
|
| [40] |
Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study[J]. J Clin Oncol,2009,27(33):5529-5537.
|
| [41] |
Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer [J]. N Engl J Med,2012,366(2):109-119.
|
| [42] |
Blackwell KL, Miles D, Gianni L, et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1)versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab(T) and a taxane[EB/OL]. [2012-11-20]. http:/ /meetinglibrary.asco.org/content/98675-114.
|
| [43] |
Wang ZH, Hu XC, Chen L, et al. Efficacy of gemcitabine and cisplatin (GP) as first-line combination therapy in patients with triple-negative metastatic breast cancer: Preliminary results report of a phase II trial[EB/OL]. [2012-12-20]. http:/ /meetinglibrary.asco.org/content/51554-74.
|
| [44] |
O’Shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib ( BSI-201 ) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC) [EB/OL]. [2012-12-20]. http:/ /meetinglibrary.asco.org/content/78038-102.
|
| [45] |
Baselga J, Gomez P, Awada A, et al. The addition of cetuximab to cisplatin increases overall response rate (ORR)and progression-free survival ( PFS) in metastatic triplenegative breast cancer (TNBC): results of a randomized phase II study ( BALI-1) [ EB/OL]. [2012-12-10]. http:/ /oncologypro. esmo. org/meeting-resources/meeting-abstracts/european-society-for-medical-oncology-esmo-2010/the-additionof-cetuximab-to-cisplatin-4625.aspx.
|